rectangular parallel plate flow chamber cat. no. 31–010 Search Results


recombinant mouse scf protein  (Bio-Techne corporation)
95
Bio-Techne corporation recombinant mouse scf protein
Recombinant Mouse Scf Protein, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant mouse scf protein/product/Bio-Techne corporation
Average 95 stars, based on 1 article reviews
recombinant mouse scf protein - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
rectangular parallel plate flow chamber cat. no. 31-010  (GlycoTech Corporation)
90
GlycoTech Corporation rectangular parallel plate flow chamber cat. no. 31-010
Rectangular Parallel Plate Flow Chamber Cat. No. 31 010, supplied by GlycoTech Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rectangular parallel plate flow chamber cat. no. 31-010/product/GlycoTech Corporation
Average 90 stars, based on 1 article reviews
rectangular parallel plate flow chamber cat. no. 31-010 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
bmp 4  (R&D Systems)
97
R&D Systems bmp 4
Bmp 4, supplied by R&D Systems, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bmp 4/product/R&D Systems
Average 97 stars, based on 1 article reviews
bmp 4 - by Bioz Stars, 2026-05
97/100 stars
  Buy from Supplier
human recombinant bmp 4  (R&D Systems)
98
R&D Systems human recombinant bmp 4
Human Recombinant Bmp 4, supplied by R&D Systems, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human recombinant bmp 4/product/R&D Systems
Average 98 stars, based on 1 article reviews
human recombinant bmp 4 - by Bioz Stars, 2026-05
98/100 stars
  Buy from Supplier
phosphate buffered saline, solution 1×, without calcium, without magnesium  (MultiCell Technologies)
90
MultiCell Technologies phosphate buffered saline, solution 1×, without calcium, without magnesium
Phosphate Buffered Saline, Solution 1×, Without Calcium, Without Magnesium, supplied by MultiCell Technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/phosphate buffered saline, solution 1×, without calcium, without magnesium/product/MultiCell Technologies
Average 90 stars, based on 1 article reviews
phosphate buffered saline, solution 1×, without calcium, without magnesium - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
hbmp2  (R&D Systems)
96
R&D Systems hbmp2
VHH specificity compared to different inhibitors. C2C12 cells were activated with 50 ng/ml of <t>hBMP2</t> (A), 10 ng/ml of hBMP4 (B), 200 ng/ml of hBMP5 (C), 50 ng/ml of hBMP6 (D), 200 ng/ml of hBMP7 (E), 25 ng/ml of hBMP9 (F), 25 ng/ml of hBMP10 (G) and 50 ng/ml of hBMP12 (H) for 16h. At the same time the inhibitors were added. VHH, mNoggin, hNoggin and Gremlin were added at a concentration of 500 ng/ml; LDN-193189 (LDN) at 0.5 μM and DMH1 at 0.2 μM.
Hbmp2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hbmp2/product/R&D Systems
Average 96 stars, based on 1 article reviews
hbmp2 - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
hbmp12  (R&D Systems)
92
R&D Systems hbmp12
VHH specificity compared to different inhibitors. C2C12 cells were activated with 50 ng/ml of hBMP2 (A), 10 ng/ml of hBMP4 (B), 200 ng/ml of hBMP5 (C), 50 ng/ml of hBMP6 (D), 200 ng/ml of hBMP7 (E), 25 ng/ml of hBMP9 (F), 25 ng/ml of hBMP10 (G) and 50 ng/ml of <t>hBMP12</t> (H) for 16h. At the same time the inhibitors were added. VHH, mNoggin, hNoggin and Gremlin were added at a concentration of 500 ng/ml; LDN-193189 (LDN) at 0.5 μM and DMH1 at 0.2 μM.
Hbmp12, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hbmp12/product/R&D Systems
Average 92 stars, based on 1 article reviews
hbmp12 - by Bioz Stars, 2026-05
92/100 stars
  Buy from Supplier
hbmp7  (R&D Systems)
95
R&D Systems hbmp7
VHH specificity compared to different inhibitors. C2C12 cells were activated with 50 ng/ml of hBMP2 (A), 10 ng/ml of hBMP4 (B), 200 ng/ml of hBMP5 (C), 50 ng/ml of hBMP6 (D), 200 ng/ml of <t>hBMP7</t> (E), 25 ng/ml of hBMP9 (F), 25 ng/ml of hBMP10 (G) and 50 ng/ml of hBMP12 (H) for 16h. At the same time the inhibitors were added. VHH, mNoggin, hNoggin and Gremlin were added at a concentration of 500 ng/ml; LDN-193189 (LDN) at 0.5 μM and DMH1 at 0.2 μM.
Hbmp7, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hbmp7/product/R&D Systems
Average 95 stars, based on 1 article reviews
hbmp7 - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
recombinant mouse bmp-9 protein  (Bio-Techne corporation)
93
Bio-Techne corporation recombinant mouse bmp-9 protein
VHH specificity compared to different inhibitors. C2C12 cells were activated with 50 ng/ml of hBMP2 (A), 10 ng/ml of hBMP4 (B), 200 ng/ml of hBMP5 (C), 50 ng/ml of hBMP6 (D), 200 ng/ml of <t>hBMP7</t> (E), 25 ng/ml of hBMP9 (F), 25 ng/ml of hBMP10 (G) and 50 ng/ml of hBMP12 (H) for 16h. At the same time the inhibitors were added. VHH, mNoggin, hNoggin and Gremlin were added at a concentration of 500 ng/ml; LDN-193189 (LDN) at 0.5 μM and DMH1 at 0.2 μM.
Recombinant Mouse Bmp 9 Protein, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant mouse bmp-9 protein/product/Bio-Techne corporation
Average 93 stars, based on 1 article reviews
recombinant mouse bmp-9 protein - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
recombinant human kgf/fgf-7 protein  (Bio-Techne corporation)
95
Bio-Techne corporation recombinant human kgf/fgf-7 protein
VHH specificity compared to different inhibitors. C2C12 cells were activated with 50 ng/ml of hBMP2 (A), 10 ng/ml of hBMP4 (B), 200 ng/ml of hBMP5 (C), 50 ng/ml of hBMP6 (D), 200 ng/ml of <t>hBMP7</t> (E), 25 ng/ml of hBMP9 (F), 25 ng/ml of hBMP10 (G) and 50 ng/ml of hBMP12 (H) for 16h. At the same time the inhibitors were added. VHH, mNoggin, hNoggin and Gremlin were added at a concentration of 500 ng/ml; LDN-193189 (LDN) at 0.5 μM and DMH1 at 0.2 μM.
Recombinant Human Kgf/Fgf 7 Protein, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human kgf/fgf-7 protein/product/Bio-Techne corporation
Average 95 stars, based on 1 article reviews
recombinant human kgf/fgf-7 protein - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
ldn-193189  (Cayman Chemical)
90
Cayman Chemical ldn-193189
VHH specificity compared to different inhibitors. C2C12 cells were activated with 50 ng/ml of hBMP2 (A), 10 ng/ml of hBMP4 (B), 200 ng/ml of hBMP5 (C), 50 ng/ml of hBMP6 (D), 200 ng/ml of <t>hBMP7</t> (E), 25 ng/ml of hBMP9 (F), 25 ng/ml of hBMP10 (G) and 50 ng/ml of hBMP12 (H) for 16h. At the same time the inhibitors were added. VHH, mNoggin, hNoggin and Gremlin were added at a concentration of 500 ng/ml; LDN-193189 (LDN) at 0.5 μM and DMH1 at 0.2 μM.
Ldn 193189, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ldn-193189/product/Cayman Chemical
Average 90 stars, based on 1 article reviews
ldn-193189 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
hbmp9  (R&D Systems)
95
R&D Systems hbmp9
VHH specificity compared to different inhibitors. C2C12 cells were activated with 50 ng/ml of hBMP2 (A), 10 ng/ml of hBMP4 (B), 200 ng/ml of hBMP5 (C), 50 ng/ml of hBMP6 (D), 200 ng/ml of hBMP7 (E), 25 ng/ml of <t>hBMP9</t> (F), 25 ng/ml of hBMP10 (G) and 50 ng/ml of hBMP12 (H) for 16h. At the same time the inhibitors were added. VHH, mNoggin, hNoggin and Gremlin were added at a concentration of 500 ng/ml; LDN-193189 (LDN) at 0.5 μM and DMH1 at 0.2 μM.
Hbmp9, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hbmp9/product/R&D Systems
Average 95 stars, based on 1 article reviews
hbmp9 - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier

Image Search Results


VHH specificity compared to different inhibitors. C2C12 cells were activated with 50 ng/ml of hBMP2 (A), 10 ng/ml of hBMP4 (B), 200 ng/ml of hBMP5 (C), 50 ng/ml of hBMP6 (D), 200 ng/ml of hBMP7 (E), 25 ng/ml of hBMP9 (F), 25 ng/ml of hBMP10 (G) and 50 ng/ml of hBMP12 (H) for 16h. At the same time the inhibitors were added. VHH, mNoggin, hNoggin and Gremlin were added at a concentration of 500 ng/ml; LDN-193189 (LDN) at 0.5 μM and DMH1 at 0.2 μM.

Journal: mAbs

Article Title: Comparison of newly developed anti-bone morphogenetic protein 4 llama-derived antibodies with commercially available BMP4 inhibitors

doi: 10.1080/19420862.2016.1158380

Figure Lengend Snippet: VHH specificity compared to different inhibitors. C2C12 cells were activated with 50 ng/ml of hBMP2 (A), 10 ng/ml of hBMP4 (B), 200 ng/ml of hBMP5 (C), 50 ng/ml of hBMP6 (D), 200 ng/ml of hBMP7 (E), 25 ng/ml of hBMP9 (F), 25 ng/ml of hBMP10 (G) and 50 ng/ml of hBMP12 (H) for 16h. At the same time the inhibitors were added. VHH, mNoggin, hNoggin and Gremlin were added at a concentration of 500 ng/ml; LDN-193189 (LDN) at 0.5 μM and DMH1 at 0.2 μM.

Article Snippet: To analyze VHH specificity, C2C12 cells were stimulated with 10 ng/ml of hBMP4 (Cat. No. 314-BP-020; R&D Systems), 50 ng/ml of hBMP2 (Cat. No. 355-BM-010; R&D Systems), 200 ng/ml of hBMP5 (Cat. No. 615-BMC-020; R&D Systems), 50 ng/ml of hBMP6 (Cat. No. 506-BP-020; R&D Systems), 200 ng/ml of hBMP7 (Cat. No. 354-BP-010; R&D Systems), 25 ng/ml of hBMP9 (Cat. No. 3209-BP-010; R&D Systems), 25 ng/ml of hBMP10 (Cat. No. 2926-BP-025; R&D Systems), and 50 ng/ml of hBMP12 (Cat. No. 779-G7-010; R&D Systems).

Techniques: Concentration Assay

Epitope mapping with hΔBMP4. Schematic alignment of hBMP2, hBMP4 and mutated BMP4 (hΔBMP4) and comparison of relative functionality of BMP4 and hΔBMP4 (A). Comparison of BMP4 binding sites between antibodies. C2C12 cells were stimulated with 10 ng/ml of BMP4 or 1,000 ng/ml of hΔBMP4. At the same time the antibodies were added at a concentration of 10 μg/ml (B).

Journal: mAbs

Article Title: Comparison of newly developed anti-bone morphogenetic protein 4 llama-derived antibodies with commercially available BMP4 inhibitors

doi: 10.1080/19420862.2016.1158380

Figure Lengend Snippet: Epitope mapping with hΔBMP4. Schematic alignment of hBMP2, hBMP4 and mutated BMP4 (hΔBMP4) and comparison of relative functionality of BMP4 and hΔBMP4 (A). Comparison of BMP4 binding sites between antibodies. C2C12 cells were stimulated with 10 ng/ml of BMP4 or 1,000 ng/ml of hΔBMP4. At the same time the antibodies were added at a concentration of 10 μg/ml (B).

Article Snippet: To analyze VHH specificity, C2C12 cells were stimulated with 10 ng/ml of hBMP4 (Cat. No. 314-BP-020; R&D Systems), 50 ng/ml of hBMP2 (Cat. No. 355-BM-010; R&D Systems), 200 ng/ml of hBMP5 (Cat. No. 615-BMC-020; R&D Systems), 50 ng/ml of hBMP6 (Cat. No. 506-BP-020; R&D Systems), 200 ng/ml of hBMP7 (Cat. No. 354-BP-010; R&D Systems), 25 ng/ml of hBMP9 (Cat. No. 3209-BP-010; R&D Systems), 25 ng/ml of hBMP10 (Cat. No. 2926-BP-025; R&D Systems), and 50 ng/ml of hBMP12 (Cat. No. 779-G7-010; R&D Systems).

Techniques: Comparison, Binding Assay, Concentration Assay

VHH specificity compared to different inhibitors. C2C12 cells were activated with 50 ng/ml of hBMP2 (A), 10 ng/ml of hBMP4 (B), 200 ng/ml of hBMP5 (C), 50 ng/ml of hBMP6 (D), 200 ng/ml of hBMP7 (E), 25 ng/ml of hBMP9 (F), 25 ng/ml of hBMP10 (G) and 50 ng/ml of hBMP12 (H) for 16h. At the same time the inhibitors were added. VHH, mNoggin, hNoggin and Gremlin were added at a concentration of 500 ng/ml; LDN-193189 (LDN) at 0.5 μM and DMH1 at 0.2 μM.

Journal: mAbs

Article Title: Comparison of newly developed anti-bone morphogenetic protein 4 llama-derived antibodies with commercially available BMP4 inhibitors

doi: 10.1080/19420862.2016.1158380

Figure Lengend Snippet: VHH specificity compared to different inhibitors. C2C12 cells were activated with 50 ng/ml of hBMP2 (A), 10 ng/ml of hBMP4 (B), 200 ng/ml of hBMP5 (C), 50 ng/ml of hBMP6 (D), 200 ng/ml of hBMP7 (E), 25 ng/ml of hBMP9 (F), 25 ng/ml of hBMP10 (G) and 50 ng/ml of hBMP12 (H) for 16h. At the same time the inhibitors were added. VHH, mNoggin, hNoggin and Gremlin were added at a concentration of 500 ng/ml; LDN-193189 (LDN) at 0.5 μM and DMH1 at 0.2 μM.

Article Snippet: To analyze VHH specificity, C2C12 cells were stimulated with 10 ng/ml of hBMP4 (Cat. No. 314-BP-020; R&D Systems), 50 ng/ml of hBMP2 (Cat. No. 355-BM-010; R&D Systems), 200 ng/ml of hBMP5 (Cat. No. 615-BMC-020; R&D Systems), 50 ng/ml of hBMP6 (Cat. No. 506-BP-020; R&D Systems), 200 ng/ml of hBMP7 (Cat. No. 354-BP-010; R&D Systems), 25 ng/ml of hBMP9 (Cat. No. 3209-BP-010; R&D Systems), 25 ng/ml of hBMP10 (Cat. No. 2926-BP-025; R&D Systems), and 50 ng/ml of hBMP12 (Cat. No. 779-G7-010; R&D Systems).

Techniques: Concentration Assay

VHH specificity compared to different inhibitors. C2C12 cells were activated with 50 ng/ml of hBMP2 (A), 10 ng/ml of hBMP4 (B), 200 ng/ml of hBMP5 (C), 50 ng/ml of hBMP6 (D), 200 ng/ml of hBMP7 (E), 25 ng/ml of hBMP9 (F), 25 ng/ml of hBMP10 (G) and 50 ng/ml of hBMP12 (H) for 16h. At the same time the inhibitors were added. VHH, mNoggin, hNoggin and Gremlin were added at a concentration of 500 ng/ml; LDN-193189 (LDN) at 0.5 μM and DMH1 at 0.2 μM.

Journal: mAbs

Article Title: Comparison of newly developed anti-bone morphogenetic protein 4 llama-derived antibodies with commercially available BMP4 inhibitors

doi: 10.1080/19420862.2016.1158380

Figure Lengend Snippet: VHH specificity compared to different inhibitors. C2C12 cells were activated with 50 ng/ml of hBMP2 (A), 10 ng/ml of hBMP4 (B), 200 ng/ml of hBMP5 (C), 50 ng/ml of hBMP6 (D), 200 ng/ml of hBMP7 (E), 25 ng/ml of hBMP9 (F), 25 ng/ml of hBMP10 (G) and 50 ng/ml of hBMP12 (H) for 16h. At the same time the inhibitors were added. VHH, mNoggin, hNoggin and Gremlin were added at a concentration of 500 ng/ml; LDN-193189 (LDN) at 0.5 μM and DMH1 at 0.2 μM.

Article Snippet: To analyze VHH specificity, C2C12 cells were stimulated with 10 ng/ml of hBMP4 (Cat. No. 314-BP-020; R&D Systems), 50 ng/ml of hBMP2 (Cat. No. 355-BM-010; R&D Systems), 200 ng/ml of hBMP5 (Cat. No. 615-BMC-020; R&D Systems), 50 ng/ml of hBMP6 (Cat. No. 506-BP-020; R&D Systems), 200 ng/ml of hBMP7 (Cat. No. 354-BP-010; R&D Systems), 25 ng/ml of hBMP9 (Cat. No. 3209-BP-010; R&D Systems), 25 ng/ml of hBMP10 (Cat. No. 2926-BP-025; R&D Systems), and 50 ng/ml of hBMP12 (Cat. No. 779-G7-010; R&D Systems).

Techniques: Concentration Assay

VHH specificity compared to different inhibitors. C2C12 cells were activated with 50 ng/ml of hBMP2 (A), 10 ng/ml of hBMP4 (B), 200 ng/ml of hBMP5 (C), 50 ng/ml of hBMP6 (D), 200 ng/ml of hBMP7 (E), 25 ng/ml of hBMP9 (F), 25 ng/ml of hBMP10 (G) and 50 ng/ml of hBMP12 (H) for 16h. At the same time the inhibitors were added. VHH, mNoggin, hNoggin and Gremlin were added at a concentration of 500 ng/ml; LDN-193189 (LDN) at 0.5 μM and DMH1 at 0.2 μM.

Journal: mAbs

Article Title: Comparison of newly developed anti-bone morphogenetic protein 4 llama-derived antibodies with commercially available BMP4 inhibitors

doi: 10.1080/19420862.2016.1158380

Figure Lengend Snippet: VHH specificity compared to different inhibitors. C2C12 cells were activated with 50 ng/ml of hBMP2 (A), 10 ng/ml of hBMP4 (B), 200 ng/ml of hBMP5 (C), 50 ng/ml of hBMP6 (D), 200 ng/ml of hBMP7 (E), 25 ng/ml of hBMP9 (F), 25 ng/ml of hBMP10 (G) and 50 ng/ml of hBMP12 (H) for 16h. At the same time the inhibitors were added. VHH, mNoggin, hNoggin and Gremlin were added at a concentration of 500 ng/ml; LDN-193189 (LDN) at 0.5 μM and DMH1 at 0.2 μM.

Article Snippet: To analyze VHH specificity, C2C12 cells were stimulated with 10 ng/ml of hBMP4 (Cat. No. 314-BP-020; R&D Systems), 50 ng/ml of hBMP2 (Cat. No. 355-BM-010; R&D Systems), 200 ng/ml of hBMP5 (Cat. No. 615-BMC-020; R&D Systems), 50 ng/ml of hBMP6 (Cat. No. 506-BP-020; R&D Systems), 200 ng/ml of hBMP7 (Cat. No. 354-BP-010; R&D Systems), 25 ng/ml of hBMP9 (Cat. No. 3209-BP-010; R&D Systems), 25 ng/ml of hBMP10 (Cat. No. 2926-BP-025; R&D Systems), and 50 ng/ml of hBMP12 (Cat. No. 779-G7-010; R&D Systems).

Techniques: Concentration Assay